Figure 5.

In vitro study of focused compounds toward JAK2/3 by kinase assay and cell-based assay. (A) In vitro IC₅₀ values of the potent quinoxalinone derivatives (MN341P, MN390, ST3i, and ST4j) and drugs (tofacitinib and ruxolitinib) toward JAK2/3 (ND = not detected), the IC₅₀ value of ST4j compound and drugs toward (B) TF1 and HEL, (C) Vero and HepG2 cells, and (D) Western blot analysis in TF1 cells after treatment with ST4j and drugs at various concentrations. * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001 vs tofacitinib, ^#p ≤ 0.05 and ^###p ≤ 0.001 vs ruxolitinib.